Abstract:Pituitary adenomas (PAs) are tumors originating in the pituitary gland, a small gland located at the base of the brain. They are the most common type of pituitary tumor, affecting approximately 1 in 10 people over their lifetime. Common symptoms include headaches, vision problems, hormonal imbalances, and weight changes. Treatment options depend on the type and size of the adenoma and may consist of medication, surgery, radiation therapy, or a combination. PAs are typically benign and slow-growing, but they can cause significant health issues if left untreated. Proper diagnosis and management by an experienced multidisciplinary team is important for achieving the best outcomes. Natural compounds like celastrol, curcumin, quercetin, apigenin, resveratrol, epigallocatechin gallate (EGCG), and genistein have shown the ability to inhibit cell growth, promote cell death, and suppress hormone activity in pituitary tumor cells, suggesting their potential as alternative or complementary treatments for PAs. MicroRNAs (miRNAs) are a kind of tiny RNA molecules that do not code for proteins and have a vital function in controlling gene expression. These 21-23 nucleotide-long molecules regulate gene expression by binding to complementary sequences in mRNA molecules, leading to mRNA degradation. miRNAs participate in a wide range of biological activities, including apoptosis, metastasis, differentiation, and proliferation. The research indicates that miRNAs play a crucial role in the pathogenesis, therapeutic approaches, diagnosis, and prognosis of PAs. This review article will provide a comprehensive analysis of the current understanding of the efficacy of naturally derived anti-cancer agents in the treatment of PAs. Furthermore, the study provides a comprehensive assessment of the miRNAs in PAs, their role in the development of PAs, and their potential application in the treatment of the condition.

The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas

Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review

Targeting Nrf2-Mediated Oxidative Stress Response Signaling Pathways as New Therapeutic Strategy for Pituitary Adenomas

The MAPK pathway across different malignancies: A new perspective

Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer

Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors

Metabolic Abnormalities in Pituitary Adenoma Patients: A Novel Therapeutic Target and Prognostic Factor

Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Precision drugging of the MAPK pathway in head and neck cancer

Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Autophagy and Pituitary Adenoma

Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review

Antineoplastic Agents Targeting on MAPK Signal Transduction System

Targeting the ERK signaling pathway in cancer therapy

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy